143 related articles for article (PubMed ID: 2682296)
1. Phenotypical study of human lymphokine-activated killer (LAK) cells.
Barral AM; García CA
Neoplasma; 1989; 36(5):583-8. PubMed ID: 2682296
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
3. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
4. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
Zollner TM; Zhu HG; Anderer FA
Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
[TBL] [Abstract][Full Text] [Related]
5. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
6. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
7. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
Savary CA; Lotzová E
Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
11. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
13. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
14. Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo.
Berthold F; Himmelmann U; Pohl U
Prog Clin Biol Res; 1991; 366():417-24. PubMed ID: 1906185
[No Abstract] [Full Text] [Related]
15. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
16. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
[TBL] [Abstract][Full Text] [Related]
18. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
[TBL] [Abstract][Full Text] [Related]
20. Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure.
Steen PD; McGregor JR; Lehman CM; Samlowski WE
J Immunol; 1989 Dec; 143(12):4324-30. PubMed ID: 2687380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]